tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robert Leboyer, 31 are a BUY (93.94%), 2 are a HOLD (6.06%).
Analyst Robert Leboyer, currently employed at NOBLE CAPITAL, carries an average stock price target met ratio of 30.36% that have a potential upside of 23.56% achieved within 207 days.
Robert Leboyer’s has documented 65 price targets and ratings displayed on 17 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on UNCY, Unicycive Therapeutics at 01-Jul-2026.
Analyst best performing recommendations are on BNTC (BENITEC BIOPHARMA LTD ADR).
The best stock recommendation documented was for BNTC (BENITEC BIOPHARMA LTD ADR) at 4/20/2020. The price target of $238 was fulfilled within 1 day with a profit of $15.98 (7.2%) receiving and performance score of 71.98.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 15-Dec-2022
3 years 8 months 5 days ago
(16-Feb-2023)
2/2 (100%)
$-38.25 (-79.27%)
301
Hold
$6
$5.15 (605.88%)
3 years 10 months 6 days ago
(15-Dec-2022)
1/1 (100%)
$-4.98 (-45.36%)
1
Buy Since 12-Oct-2021
$225
$220.42 (4812.66%)
$150
3 years 11 months 19 days ago
(02-Nov-2022)
0/2 (0%)
$199.25 (773.79%)
Buy Since 03-Jun-2021
$175
3 years 11 months 19 days ago
(02-Nov-2022)
0/2 (0%)
$131.5 (302.30%)
Buy Since 03-Jun-2019
4 years 2 months 18 days ago
(03-Aug-2022)
0/3 (0%)
$139.25 (125.73%)
Which stock is Robert Leboyer most bullish on?
What Year was the first public recommendation made by Robert Leboyer?
